FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1769272814> ?p ?o ?g. }

• W1769272814 endingPage "32" @default.
• W1769272814 startingPage "1323" @default.
• W1769272814 abstract "Angiogenesis plays an important role in colorectal cancer progression. Stimulation of vascular endothelial growth factor receptor (VEGFR), a transmembrane glycoprotein, results in endothelial mitogenesis. Within this family of receptors, VEGFR 2/kinase-insert-domain-containing receptor (KDR) appear to be principally up-regulated during tumorigenesis. A chimeric anti-KDR antibody, IMC-1C11, blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation. This trial seeks to assess the safety, tolerability and feasibility of targeting an important pathway in tumorigenesis.In a dose-escalation, single-agent study of IMC-1C11, we enrolled 14 patients with colorectal carcinoma and hepatic metastases. Safety-, pharmacokinetic-, immunogenicity-, and magnetic resonance imaging-assessed alteration of vascular effects of IMC-1C11 were evaluated in this trial. IMC-1C11 was infused weekly at 0.2 mg/kg (n = 3), 0.6 mg/kg (n = 4), 2.0 mg/kg (n = 3), and 4.0 mg/kg (n = 4) for 4 weeks, which constituted a cycle.No grade-3 or -4 IMC-1C11-related toxicities were observed. Minor grade-1 bleeding events were observed in four patients [0.2 mg/kg (n = 1) and 0.6 mg/kg (n = 3)]. Each resolved quickly and required no intervention. The starting dose of IMC-1C11 was selected to achieve a C(max) of approximately 5 micro g/ml. This concentration prevented KDR phosphorylation in vitro. Pharmacokinetic analysis demonstrated that the plasma t(1/2) and C(max) were dose dependent with a plasma t(1/2) of 67 +/- 3 h at the 4-mg/kg dose level. Human antichimeric antibodies were detected in 7 of 14 patients. The antibodies to IMC-1C11 inhibited the circulation of the agent in two patients. One patient had prolonged stable disease for seven cycles (28 weeks). The mean changes in tumor-influx volume-transfer constant k(in) (min(-1)) and enhancement factor after 4 weeks of therapy were significantly decreased compared with pretreatment values in 11 patients.IMC-1C11 was both safe and well tolerated. Drug levels of IMC-1C11 were reliably predicted. Further clinical investigation of anti-VEGFR/KDR agents is warranted." @default.
• W1769272814 created "2016-06-24" @default.
• W1769272814 creator A5005234747 @default.
• W1769272814 creator A5005674496 @default.
• W1769272814 creator A5021610077 @default.
• W1769272814 creator A5021891056 @default.
• W1769272814 creator A5023162083 @default.
• W1769272814 creator A5047996868 @default.
• W1769272814 creator A5061924686 @default.
• W1769272814 creator A5089379108 @default.
• W1769272814 creator A5089748359 @default.
• W1769272814 date "2003-04-01" @default.
• W1769272814 modified "2023-09-23" @default.
• W1769272814 title "A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma." @default.
• W1769272814 cites W1556933114 @default.
• W1769272814 cites W1593130318 @default.
• W1769272814 cites W1604140953 @default.
• W1769272814 cites W1756949381 @default.
• W1769272814 cites W1838036926 @default.
• W1769272814 cites W1855071553 @default.
• W1769272814 cites W1964238095 @default.
• W1769272814 cites W1967007810 @default.
• W1769272814 cites W1970053353 @default.
• W1769272814 cites W1970730148 @default.
• W1769272814 cites W1974165456 @default.
• W1769272814 cites W1992105917 @default.
• W1769272814 cites W2003366243 @default.
• W1769272814 cites W2020734799 @default.
• W1769272814 cites W2040972148 @default.
• W1769272814 cites W2049292409 @default.
• W1769272814 cites W2049852228 @default.
• W1769272814 cites W2050105922 @default.
• W1769272814 cites W2054607457 @default.
• W1769272814 cites W2096481282 @default.
• W1769272814 cites W2100525694 @default.
• W1769272814 cites W2109509015 @default.
• W1769272814 cites W2111080918 @default.
• W1769272814 cites W2112476236 @default.
• W1769272814 cites W2117842006 @default.
• W1769272814 cites W2141046053 @default.
• W1769272814 cites W2144874683 @default.
• W1769272814 cites W2153839353 @default.
• W1769272814 cites W2161688555 @default.
• W1769272814 cites W2167531081 @default.
• W1769272814 cites W2185838453 @default.
• W1769272814 cites W2232660545 @default.
• W1769272814 cites W2399932359 @default.
• W1769272814 cites W2413219779 @default.
• W1769272814 cites W2421259023 @default.
• W1769272814 cites W308127573 @default.
• W1769272814 cites W3102812175 @default.
• W1769272814 cites W72110172 @default.
• W1769272814 cites W72344367 @default.
• W1769272814 cites W113067357 @default.
• W1769272814 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12684400" @default.
• W1769272814 hasPublicationYear "2003" @default.
• W1769272814 type Work @default.
• W1769272814 sameAs 1769272814 @default.
• W1769272814 citedByCount "42" @default.
• W1769272814 countsByYear W17692728142012 @default.
• W1769272814 countsByYear W17692728142013 @default.
• W1769272814 countsByYear W17692728142014 @default.
• W1769272814 countsByYear W17692728142015 @default.
• W1769272814 countsByYear W17692728142016 @default.
• W1769272814 countsByYear W17692728142018 @default.
• W1769272814 countsByYear W17692728142019 @default.
• W1769272814 crossrefType "journal-article" @default.
• W1769272814 hasAuthorship W1769272814A5005234747 @default.
• W1769272814 hasAuthorship W1769272814A5005674496 @default.
• W1769272814 hasAuthorship W1769272814A5021610077 @default.
• W1769272814 hasAuthorship W1769272814A5021891056 @default.
• W1769272814 hasAuthorship W1769272814A5023162083 @default.
• W1769272814 hasAuthorship W1769272814A5047996868 @default.
• W1769272814 hasAuthorship W1769272814A5061924686 @default.
• W1769272814 hasAuthorship W1769272814A5089379108 @default.
• W1769272814 hasAuthorship W1769272814A5089748359 @default.
• W1769272814 hasConcept C112705442 @default.
• W1769272814 hasConcept C121608353 @default.
• W1769272814 hasConcept C126322002 @default.
• W1769272814 hasConcept C134018914 @default.
• W1769272814 hasConcept C146285616 @default.
• W1769272814 hasConcept C14858245 @default.
• W1769272814 hasConcept C167734588 @default.
• W1769272814 hasConcept C170493617 @default.
• W1769272814 hasConcept C2777025900 @default.
• W1769272814 hasConcept C2780394083 @default.
• W1769272814 hasConcept C502942594 @default.
• W1769272814 hasConcept C526805850 @default.
• W1769272814 hasConcept C555283112 @default.
• W1769272814 hasConcept C71924100 @default.
• W1769272814 hasConceptScore W1769272814C112705442 @default.
• W1769272814 hasConceptScore W1769272814C121608353 @default.
• W1769272814 hasConceptScore W1769272814C126322002 @default.
• W1769272814 hasConceptScore W1769272814C134018914 @default.
• W1769272814 hasConceptScore W1769272814C146285616 @default.
• W1769272814 hasConceptScore W1769272814C14858245 @default.
• W1769272814 hasConceptScore W1769272814C167734588 @default.
• W1769272814 hasConceptScore W1769272814C170493617 @default.

• next